[A19-48] Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V

Last updated 02.09.2019

Project no.:
A19-48

Commission:
Commission awarded on 29.05.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with ALK-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or after crizotinib and at least one other ALK TKI

Result of dossier assessment:

Added benefit versus appropriate comparator therapy not proven due to a lack of suitable study data

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-11-22 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.